Hims & Hers Health operates a direct-to-consumer telehealth platform built on a recurring subscription model. The company scales digital consultations and pharmacy services, making it a high-beta growth stock sensitive to expansion and contraction cycles.
On the weekly chart, the prior impulsive move to 70+ has completed, and the market is developing an ABC corrective structure. Wave A declined toward 24, wave B retraced back toward 70, and wave C is currently unfolding.
Using a 1.272 projection of the AB move, the calculated completion zone for wave C is approximately 11.41. Current price at 16.30 indicates C remains in progress. The 11–12 region also aligns with the long-term rising diagonal support, strengthening the technical significance of that zone.
Indicators show momentum deceleration rather than reversal. ADX is declining, signaling weakening trend strength. DI− remains dominant but without acceleration. RSI is approaching oversold territory, and Stochastic is positioned in the lower range. This reflects exhaustion of downside impulse, not confirmed accumulation.
The structural focus is clear: potential completion of wave C near 11–12. Confirmation requires a local higher low and a recovery above 25–26 to shift structure back into expansion.
Before growth resumes, markets often reset excess.
On the weekly chart, the prior impulsive move to 70+ has completed, and the market is developing an ABC corrective structure. Wave A declined toward 24, wave B retraced back toward 70, and wave C is currently unfolding.
Using a 1.272 projection of the AB move, the calculated completion zone for wave C is approximately 11.41. Current price at 16.30 indicates C remains in progress. The 11–12 region also aligns with the long-term rising diagonal support, strengthening the technical significance of that zone.
Indicators show momentum deceleration rather than reversal. ADX is declining, signaling weakening trend strength. DI− remains dominant but without acceleration. RSI is approaching oversold territory, and Stochastic is positioned in the lower range. This reflects exhaustion of downside impulse, not confirmed accumulation.
The structural focus is clear: potential completion of wave C near 11–12. Confirmation requires a local higher low and a recovery above 25–26 to shift structure back into expansion.
Before growth resumes, markets often reset excess.
노트
Friends, hello.Hims & Hers and Novo Nordisk have officially announced a partnership. The deal is closed despite recent legal disputes between the companies.
Novo Nordisk will sell its weight loss drugs through the Hims & Hers platform. For Hims, this means access to original medications and relief from regulatory risks. For Novo, it's access to an audience of over 2 million subscribers and a sales channel without competition from generics.
Just in February, Novo filed a lawsuit against Hims for infringing patent rights on semaglutide. The trigger was Hims launching a copycat version of Wegovy in pill form. Under regulatory pressure, Hims halted sales. A year earlier, a similar agreement had already fallen through: Hims refused to stop selling compounded versions of Novo's drugs even after the US shortage ended.
The market responded with gains. Hims stock surged 40%. Novo shares added about 2%. Eli Lilly, Novo's main competitor in the GLP-1 segment, remained unchanged.
Novo had previously partnered with Ro and Weight Watchers without conflicts. Regulatory pressure on Hims continues: the company is being investigated by the SEC. The partnership with Novo reduces these risks and legitimizes the company's presence in the weight loss drug segment.
액티브 트레이드
HIMS +70%. A return above 25–26 would confirm the transition to a new growth phase.거래청산: 타겟 닿음
📊 Trader | Analysis & Trade Ideas
📲 Telegram → t.me/totoshkatradingteam
FxPro → direct.cis-fxpro.trade/ru/partner/SwHtc7m3?platform=web
AMarkets → profit-market.info/promo/?g=BZA6ZC
📲 Telegram → t.me/totoshkatradingteam
FxPro → direct.cis-fxpro.trade/ru/partner/SwHtc7m3?platform=web
AMarkets → profit-market.info/promo/?g=BZA6ZC
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
📊 Trader | Analysis & Trade Ideas
📲 Telegram → t.me/totoshkatradingteam
FxPro → direct.cis-fxpro.trade/ru/partner/SwHtc7m3?platform=web
AMarkets → profit-market.info/promo/?g=BZA6ZC
📲 Telegram → t.me/totoshkatradingteam
FxPro → direct.cis-fxpro.trade/ru/partner/SwHtc7m3?platform=web
AMarkets → profit-market.info/promo/?g=BZA6ZC
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.